Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 9/20 | 0.80 |
| ▸ | MAPT | P10636 | 6/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.80 |
| ▸ | BACE1 | P56817 | 3/20 | 0.80 |
| ▸ | MMP9 | P14780 | 3/20 | 0.80 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.80 |
| ▸ | STAT3 | P40763 | 3/20 | 0.80 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.80 |
| ▸ | RELA | Q04206 | 3/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.80 |
| ▸ | TSHR | P16473 | 2/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.80 |
| ▸ | PTGES | O14684 | 2/20 | 0.80 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.80 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.80 |
| ▸ | MAOA | P21397 | 2/20 | 0.80 |
| ▸ | MAOB | P27338 | 2/20 | 0.80 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.80 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27996197 | 0.99 | APP (0.78) | APPMAPTNFKB1CYP2D6BACE1 | |
| SCHEMBL933340 | 0.90 | APP (0.91) | APPMAPTNFKB1CYP2D6BACE1 | |
| SCHEMBL1646540 | 0.89 | APP (0.89) | APPMAPTNFKB1CYP2D6BACE1 | |
| SCHEMBL29924151 | 0.89 | APP (0.89) | APPMAPTNFKB1CYP2D6BACE1 | |
| SCHEMBL1646542 | 0.89 | APP (0.89) | APPMAPTNFKB1CYP2D6BACE1 | |
| SCHEMBL29985625 | 0.89 | APP (0.89) | APPMAPTNFKB1CYP2D6BACE1 | |
| Curcumin SCHEMBL2177792 | 0.89 | APP (0.94) | APPMAPTNFKB1CYP2D6BACE1 | |
| Curcumin SCHEMBL40025 | 0.89 | APP (0.94) | APPMAPTNFKB1CYP2D6BACE1 | |
| Curcumin SCHEMBL20562725 | 0.89 | APP (0.94) | APPMAPTNFKB1CYP2D6BACE1 | |
| Curcumin SCHEMBL2177794 | 0.89 | APP (0.94) | APPMAPTNFKB1CYP2D6BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180852-A1 | TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS | SIGNPATH PHARMA, INC. | 2024-06-06 | — | — | US | claimed |
| EP-4301469-A1 | TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS | Signpath Pharma, Inc. (US) | 2024-01-10 | — | — | EP | claimed |
| CN-116710123-A | Cytokine release and inhibition of cytokine storm | 萨恩帕斯药物有限公司 | 2023-09-05 | — | — | CN | claimed |
| EP-4188398-A1 | SUPPRESSION OF CYTOKINE RELEASE AND CYTOKINE STORM | Signpath Pharma, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2022187351-A1 | TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS | SIGNPATH PHARMA, INC (US) | 2022-09-09 | — | — | WO | claimed |
| WO-2022026170-A1 | SUPPRESSION OF CYTOKINE RELEASE AND CYTOKINE STORM | SIGNPATH PHARMA, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| US-20200360300-A1 | Suppression of Cytokine Release and Cytokine Storm | SIGNPATH PHARMA, INC. | 2020-11-19 | — | — | US | claimed |
| US-10739353-B2 | Suppression of cytokine release and cytokine storm | SIGNPATH PHARMA, INC. (US) | 2020-08-11 | — | — | US | claimed |
| US-20190105287-A1 | Liposomal Curcumin for Treatment of Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-04-11 | — | — | US | claimed |
| US-20180318217-A1 | Liposomal Curcumin for Treatment of Diseases | SIGNPATH PHARMA INC. | 2018-11-08 | — | — | US | claimed |
| US-8784881-B2 | Liposomal curcumin for treatment of diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-07-22 | — | — | US | claimed |
| US-20130029922-A1 | FORMULATIONS FROM NATURAL PRODUCTS, TURMERIC, PACLITAXEL, AND ASPIRIN | ORGANOMED CORPORATION (US) | 2013-01-31 | — | — | US | claimed |
| US-20110287085-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-11-24 | — | — | US | claimed |
| WO-2011082290-A2 | FORMULATIONS FROM NATURAL PRODUCTS, TURMERIC, AND ASPIRIN | ORGANOMED CORPORATION (US) | 2011-07-07 | — | — | WO | claimed |
| US-20100316631-A1 | Water Soluble Curcumin-Based Compounds | THE UAB RESEARCH FOUNDATION (US) | 2010-12-16 | — | — | US | claimed |
| US-20080138400-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; anticarcinogenic and antiproliferative agents; parenteral colloidal drug delivery system providing improved bioavailability | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-06-12 | — | — | US | claimed |
| WO-2008051474-A1 | WATER SOLUBLE CURCUMIN-BASED COMPOUNDS | THE UAB RESEARCH FOUNDATION (US) | 2008-05-02 | — | — | WO | claimed |
| US-20080103213-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF NEUROFIBROMATOSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-05-01 | — | — | US | claimed |
| US-20060067998-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; parenteral colloidal drug delivery system providing improved bioavailability | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-03-30 | — | — | US | claimed |
| WO-2004080396-A2 | LIPOSOMAL CURCUMIN FOR TREATMENT OF CANCER | THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER (US) | 2004-09-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060067998-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; parenteral colloidal drug delivery system providing improved bioavailability | PNLIP, SGMS2, SGMS1 | APP 904/4885MAPT 850/4885NFKB1 2153/4885 |
| US-20130029922-A1 | FORMULATIONS FROM NATURAL PRODUCTS, TURMERIC, PACLITAXEL, AND ASPIRIN | PTGES, PTGES2, PTGES3 | APP 639/4885MAPT 499/4885NFKB1 38/4885 |
| US-20190105287-A1 | Liposomal Curcumin for Treatment of Cancer | PNLIP, BRCA1, IAPP | APP 2489/4885MAPT 1839/4885NFKB1 270/4885 |
| US-20240180852-A1 | TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS | MTDH, PLEC, LPCAT3 | APP 3737/4885MAPT 3156/4885NFKB1 793/4885 |
| US-20200360300-A1 | Suppression of Cytokine Release and Cytokine Storm | TNF, IL6, IL1B | APP 366/4885MAPT 1287/4885NFKB1 203/4885 |
| US-20110287085-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF CANCER | PNLIP, BRCA1, IAPP | APP 2489/4885MAPT 1839/4885NFKB1 270/4885 |
| US-20180318217-A1 | Liposomal Curcumin for Treatment of Diseases | LIPA, LPCAT3, LCLAT1 | APP 1019/4885MAPT 1067/4885NFKB1 179/4885 |
| US-20080138400-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; anticarcinogenic and antiproliferative agents; parenteral colloidal drug delivery system providing improved bioavailability | LCAT, SGMS2, SGMS1 | APP 1631/4885MAPT 1252/4885NFKB1 2326/4885 |
| US-10739353-B2 | Suppression of cytokine release and cytokine storm | TNF, IL2, IL6 | APP 369/4885MAPT 1425/4885NFKB1 166/4885 |
| US-20080103213-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF NEUROFIBROMATOSIS | MEN1, VHL, CALM1 | APP 168/4885MAPT 1677/4885NFKB1 205/4885 |
| US-20100316631-A1 | Water Soluble Curcumin-Based Compounds | BAD, TP53, CD14 | APP 2374/4885MAPT 2205/4885NFKB1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.